
Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) – HC Wainwright cut their FY2026 earnings per share estimates for shares of Kyverna Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.71) per share for the year, down from their previous forecast of ($2.70). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.78) EPS.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01.
Check Out Our Latest Stock Report on Kyverna Therapeutics
Kyverna Therapeutics Stock Performance
NASDAQ:KYTX opened at $4.48 on Tuesday. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.19. Kyverna Therapeutics has a fifty-two week low of $4.40 and a fifty-two week high of $13.67. The stock has a market cap of $283.23 million, a PE ratio of -1.62 and a beta of 2.12. The firm’s fifty day simple moving average is $6.02 and its 200-day simple moving average is $7.83.
Institutional Investors Weigh In On Kyverna Therapeutics
Hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC acquired a new position in Kyverna Therapeutics in the third quarter valued at $488,000. Goldman Sachs Group Inc. increased its stake in Kyverna Therapeutics by 64.6% during the third quarter. Goldman Sachs Group Inc. now owns 551,899 shares of the company’s stock worth $3,753,000 after acquiring an additional 216,669 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $498,000. Empowered Funds LLC purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $127,000. Finally, Kovack Advisors Inc. purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $65,000. 18.08% of the stock is owned by institutional investors and hedge funds.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.
Recommended Stories
- Five stocks we like better than Kyverna Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
